Enhanced Group Inc. (LS:A427H4) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of class A shares Update: US$15M · US$7.11 a share · Oppenheimer & Co. Inc. +1 Dealers: Oppenheimer & Co. Inc. (lead), Canaccord Genuity LLC (co-lead) Buyers: Apeiron (Enhanced's controlling stockholder; participates in the PIPE financing) Insiders: Apeiron, Enhanced's controlling stockholder, participates in the PIPE financing; its participation was reviewed by a special committee of independent directors. Use of proceeds: Growth of sporting, telehealth and performance products businesses, supporting DEAG's buy-and-build strategy and general corporate purposes | Nov 12, 2026 |
| Private placement of pIPE equity Tranche closed: US$50M raised · US$3.89 a share · Warrants at US$3.89 · Cantor Dealers: Cantor (lead) Buyers: Apeiron Investment Group ($20 million; lead investor); Maximilian Martin ($5 million) Insiders: Led by Apeiron Investment Group, the family office of Co-Founder and Chairman Christian Angermayer ($20 million), with participation from Co-Founder and CEO Maximilian Martin ($5 million) Use of proceeds: Path to operational profitability in 2027 and accelerating the buildout of its Performance Medicine platform | Jun 18, 2026 |